Detalles de la búsqueda
1.
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Blood
; 141(6): 579-591, 2023 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36130300
2.
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Haematologica
; 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38426294
3.
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Am J Hematol
; 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38856176
4.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol
; 98(5): 720-729, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36708469
5.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 393(10168): 253-264, 2019 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30545780
6.
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Ann Hematol
; 99(8): 1793-1804, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32613281
7.
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Br J Haematol
; 184(4): 536-546, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30460684
8.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Eur J Haematol
; 102(6): 494-503, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30943323
9.
Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
Br J Haematol
; 175(4): 705-713, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27507431
10.
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Invest New Drugs
; 34(3): 338-46, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27039387
11.
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Ann Hematol
; 100(1): 297-302, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33106909
12.
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Br J Clin Pharmacol
; 82(3): 728-38, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27121262
13.
Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents.
J Pediatr Hematol Oncol
; 35(4): 289-98, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23612380
14.
Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma: Exposure-Response Analysis of the TOURMALINE-MM4 Study.
Clin Pharmacol Ther
; 114(1): 220-229, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37186295
15.
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Blood Cancer J
; 13(1): 14, 2023 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36631458
16.
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Clin Lymphoma Myeloma Leuk
; 23(7): 491-504, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37149398
17.
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
EJHaem
; 4(4): 995-1005, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38024593
18.
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).
Br J Haematol
; 157(5): 627-36, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22463614
19.
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
Am J Hematol
; 87(11): 1017-21, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22887019
20.
Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients.
CPT Pharmacometrics Syst Pharmacol
; 11(8): 1085-1099, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598166